Efficiency of creating IPS cells from 1 to 100%

Collapse
X
 
  • Time
  • Show
Clear All
new posts

  • Arashi
    replied
    Originally posted by Desmond84
    Hey Arashi

    From what I undrestood we are having great difficulties expanding adult stem cells in culture and when we do there is insufficient numbers to do anything of importance with them! Here's a segment from one of my books on stem cells that clarifies this really well:

    Adult stem cells
    Tissue-specific stem cells in adult individuals tend to be rare. Furthermore, while they can regenerate themselves in an animal or person they are generally very difficult to grow and to expand in the laboratory. Because of this, it is difficult to obtain sufficient numbers of many adult stem cell types for study and clinical use. Hematopoietic or blood-forming stem cells in the bone marrow, for example, only make up one in a hundred thousand cells of the bone marrow. They can be isolated, but can only be expanded a very limited amount in the laboratory. Fortunately, large numbers of whole bone marrow cells can be isolated and administered for the treatment for a variety of diseases of the blood. Skin stem cells can be expanded however, and are used to treat burns. For other types of stem cells, such as mesenchymal stem cells, some success has been achieved in expanding the cells in vitro, but application in animals has been difficult. One major problem is the mode of administration. Bone marrow cells can be infused in the blood stream, and will find their way to the bone marrow. For other stem cells, such as muscle stem cells, mesenchymal stem cells and neural stem cells, the route of administration in humans is more problematic. It is believed, however, that once healthy stem cells find their niche, they will start repairing the tissue. In another approach, attempts are made to differentiate stem cells into functional tissue, which is then transplanted. A final problem is rejection. If stem cells from the patients are used, rejection by the immune system is not a problem. However, with donor stem cells, the immune system of the recipient will reject the cells, unless the immune system is suppressed by drugs. In the case of bone marrow transplantation, another problem arises. The bone marrow contains immune cells from the donor. These will attack the tissues of the recipient, causing the sometimes deadly graft-versus-host disease.

    Pluripotent stem cells
    All embryonic stem cell lines are derived from very early stage embryos, and will therefore be genetically different from any patient. Hence, immune rejection will be major issue. For this reason, iPS cells, which are generated from the cells of the patient through a process of reprogramming, are a major breakthrough, since these will not be rejected.

    A major advantage of pluripotent cells is that they can be grown and expanded indefinitely in the laboratory. Therefore, in contrast to adult stem cells, cell number will be less of a limiting factor. Another advantage is that given their very broad potential, several cell types that are present in an organ might be generated. Sophisticated tissue engineering approaches are therefore being developed to reconstruct organs in the lab.
    Thanks for your elaborate answer Desmond, much appreciated ! So this answers why we need IPS cells.

    Leave a comment:


  • Desmond84
    replied
    Hey Arashi

    From what I undrestood we are having great difficulties expanding adult stem cells in culture and when we do there is insufficient numbers to do anything of importance with them! Here's a segment from one of my books on stem cells that clarifies this really well:

    Adult stem cells
    Tissue-specific stem cells in adult individuals tend to be rare. Furthermore, while they can regenerate themselves in an animal or person they are generally very difficult to grow and to expand in the laboratory. Because of this, it is difficult to obtain sufficient numbers of many adult stem cell types for study and clinical use. Hematopoietic or blood-forming stem cells in the bone marrow, for example, only make up one in a hundred thousand cells of the bone marrow. They can be isolated, but can only be expanded a very limited amount in the laboratory. Fortunately, large numbers of whole bone marrow cells can be isolated and administered for the treatment for a variety of diseases of the blood. Skin stem cells can be expanded however, and are used to treat burns. For other types of stem cells, such as mesenchymal stem cells, some success has been achieved in expanding the cells in vitro, but application in animals has been difficult. One major problem is the mode of administration. Bone marrow cells can be infused in the blood stream, and will find their way to the bone marrow. For other stem cells, such as muscle stem cells, mesenchymal stem cells and neural stem cells, the route of administration in humans is more problematic. It is believed, however, that once healthy stem cells find their niche, they will start repairing the tissue. In another approach, attempts are made to differentiate stem cells into functional tissue, which is then transplanted. A final problem is rejection. If stem cells from the patients are used, rejection by the immune system is not a problem. However, with donor stem cells, the immune system of the recipient will reject the cells, unless the immune system is suppressed by drugs. In the case of bone marrow transplantation, another problem arises. The bone marrow contains immune cells from the donor. These will attack the tissues of the recipient, causing the sometimes deadly graft-versus-host disease.

    Pluripotent stem cells
    All embryonic stem cell lines are derived from very early stage embryos, and will therefore be genetically different from any patient. Hence, immune rejection will be major issue. For this reason, iPS cells, which are generated from the cells of the patient through a process of reprogramming, are a major breakthrough, since these will not be rejected.

    A major advantage of pluripotent cells is that they can be grown and expanded indefinitely in the laboratory. Therefore, in contrast to adult stem cells, cell number will be less of a limiting factor. Another advantage is that given their very broad potential, several cell types that are present in an organ might be generated. Sophisticated tissue engineering approaches are therefore being developed to reconstruct organs in the lab.

    Leave a comment:


  • Arashi
    replied
    Originally posted by TravisB
    So is there any chance something good for us will come out of this before 2020?
    It depends. Things are going damn fast now with huge breakthroughs like these. And the great thing is that they're located in Japan, which have recently approved the first iPS trial.

    In fact I don't see what's in the way anymore of starting trials right now.

    Question though for people like Desmond: isn't is possible to just culture existing mesenchymal cells and epitelial cells instead of converting them from skin cells ? Much like Nigams does with DP cells ?

    Leave a comment:


  • TravisB
    replied
    So is there any chance something good for us will come out of this before 2020?

    Leave a comment:


  • HairBane
    replied
    Originally posted by Arashi
    The whole idea is they biogenerate hair follicles in the lab, created from 'hair germ' which in turn is created from epithelial stem cells and mesenchymal stem cells. Then they transplant the generated cells onto the scalp, probably with an injection indeed.

    Read more: http://stemcelltherapyreviewjournal....-for-baldness/
    Sounds good, a unique approach? Thanks brother

    Leave a comment:


  • Arashi
    replied
    Originally posted by HairBane
    Could someone briefly explain, are Team Tokyo working on an injectable treatment?
    The whole idea is they biogenerate hair follicles in the lab, created from 'hair germ' which in turn is created from epithelial stem cells and mesenchymal stem cells. Then they transplant the generated cells onto the scalp, probably with an injection indeed.

    Read more: http://stemcelltherapyreviewjournal....-for-baldness/

    Leave a comment:


  • HairBane
    replied
    Could someone briefly explain, are Team Tokyo working on an injectable treatment?

    Leave a comment:


  • Arashi
    replied
    Originally posted by mari0s
    but why do you relate so much in ips cells? Tsuji and other have proved that they don't need ips stem cell and can do neogenesis even with the right interation of mesenchymal DP cells and epitelial cells. Sitting around and wait 5 years just only to see the safety of first human IPS trial, should be a waist of time.
    Correct me if I'm wrong here but isn't the whole idea is to to manufacture these Mesenchymal stem cell from skin cells ? If a skin biopsy can be used and quickly turned into Mesenchymal stem cell and Epithelial stem cells, then we're good to go, right ?I thought that was the whole idea of their procedure. http://www.tsuji-lab.com/en/research...eneration.html

    Leave a comment:


  • mari0s
    replied
    but why do you relate so much in ips cells? Tsuji and other have proved that they don't need ips stem cell and can do neogenesis even with the right interation of mesenchymal DP cells and epitelial cells. Sitting around and wait 5 years just only to see the safety of first human IPS trial, should be a waist of time.

    Leave a comment:


  • Arashi
    replied
    Also keep in mind that the first ever human clinical trial with IPS cells has recently started and is now recruiting. Also in Japan of course, which seems to have taken the world leading position regarding stem cells. http://www.rikenresearch.riken.jp/eng/roundup/7499.html
    You can bet Team Tokyo is keeping a close eye on all these developments. In fact, since all regulatory hurdles in Japan have been cleared, I'm hoping they're going to start their own trails within 18 months (like they planned)

    Leave a comment:


  • Pentarou
    replied
    Originally posted by TravisB
    10 YEARS?

    That's WAY too long

    However, if in 10 years I will be able to regain all my hair for a reasonable price, I'll still gladly take it
    Read Desmond's post again.

    Leave a comment:


  • TravisB
    replied
    Originally posted by Desmond84
    “There is a need for a number of improvements, including magnification techniques for stem cells, before the method is applied to a large surface as in humans,” Dr. Tsuji says. “We are looking at some 10 years from now.”
    10 YEARS?

    That's WAY too long

    However, if in 10 years I will be able to regain all my hair for a reasonable price, I'll still gladly take it

    Leave a comment:


  • hellouser
    replied
    Originally posted by clandestine
    Haha if BTT were a person, they would most certainly be bipolar.

    Good news, though.
    Baldness will do that to you

    Leave a comment:


  • clandestine
    replied
    Haha if BTT were a person, they would most certainly be bipolar.

    Good news, though.

    Leave a comment:


  • Desmond84
    replied
    Here's a recap of the final part of the interview with Dr Tsuji in May 2012 regarding what's holding them back:

    “There is a need for a number of improvements, including magnification techniques for stem cells, before the method is applied to a large surface as in humans,” Dr. Tsuji says. “We are looking at some 10 years from now.”

    I don't even think Dr Tsuji was expecting such a major breakthrough within one year of their results!

    This will snowball into major medical breakthroughs and trials over the next few years

    Leave a comment:

Working...